Navigation Links
Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
Date:8/21/2008

ior scientist, Stephen Dewey, Ph.D. (Dr. Dewey is the Chairman of Catalyst's Scientific Advisory Board). The Brookhaven National Laboratory press release may be accessed at http://www.bnl.gov/bnlweb/pubaf/pr/PR_display.asp?prID=811.

Commenting on today's news, Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceutical Partners, noted, "We are very encouraged by this new animal data, which shows the long-term prospects of using vigabatrin for the treatment of obesity, which is currently at epidemic proportions in the U.S. In addition to development of CPP-109 for treatment of cocaine, methamphetamine and other substance addictions, the compound appears to provide a platform for multiple indications, including as a potential treatment for obsessive compulsive disorders. In fact, as previously reported, we are currently seeking to conduct a Phase II clinical trial later this year evaluating CPP-109 for the treatment of binge eating disorder."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for eleven patents and two patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate is CPP-109, which is Catalyst's version of vigabatrin. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FD
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
2. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
3. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
4. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
5. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
6. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
7. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
10. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
11. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories ... active pharmaceutical ingredients (APIs), complex intermediates ... located in 85 countries, today announced financial results ... 2015, ended June 30, 2014. "Neuland,s ... work flow re-prioritization to accommodate certain customer needs, ...
(Date:8/1/2014)... 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep ... Industry" and "2014 Deep Research Report on Global ... its research database. Photo - ... Research Report on Global and China Potassium Nitrate ... on China and Global ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
Breaking Medicine Technology:Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30
... 19, 2012  The Specialty Photonics Division of OFS ... optical fiber, cable, and assemblies for medical device ... "Optical fibers with polyimide coatings for medical applications" ... will present on Sunday, January 22nd at 12:10 ...
... 19, 2012 RESMED INC. (NYSE: RMD ), announced ... results for the second quarter and six months of fiscal year ... will be issued after 1:00 p.m. Pacific Time and the company ... market trends, and future outlook. Please note only the "outside ...
Cached Medicine Technology:OFS to Present Paper on Optical Fibers with Polyimide Coatings for Medical Applications 2ResMed Announces Change to Outside US Dial-in Number for Conference Call and Webcast to Discuss Second Quarter 2012 Results 2
(Date:8/2/2014)... CEDR HR Solutions , a ... of customized medical and dental employee handbooks, has announced ... fall. CEDR’s CEO will be featured as a speaker ... , From September 4-6, CEDR will attend the 10th ... Managers Conference in San Diego, to be held at ...
(Date:8/1/2014)... (PRWEB) August 02, 2014 Recently, iFitDress.com, one ... unveiled its new assortment of top bridesmaid dresses ... provided at promotional prices, up to 52% off. According to ... the middle of August. , The company’s stock is ... should visit its online store as soon as possible. All ...
(Date:8/1/2014)... University School of Medicine in St. Louis helps explain ... frequently are more harmful than similar tumors in females. ... are diagnosed twice as often in males, who suffer ... as long. , The researchers found that retinoblastoma protein ... significantly less active in male brain cells than in ...
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... filed in the wake of the 2012 Rejuvenate ... to move forward in New Jersey’s Bergen County ... documents filed in the proceeding, the Court has ... of Confidentiality governing any and all hard copy ...
(Date:8/1/2014)... 2014 As it continues to investigate ... who allegedly experienced the spread of uterine cancers due ... Bernstein Liebhard LLP notes the growing reaction to Johnson ... morcellators marketed by its Ethicon, Inc. unit from the ... Times, some critics of the company said they were ...
Breaking Medicine News(10 mins):Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4
... than 500 Workers, WASHINGTON, May 16 ... the Greater Portland, Oregon and,Vancouver, Washington area have ... are pleased that these workers are now covered ... and a secure retirement,future," said Teamsters General President ...
... fibroids located just beneath the lining of the uterus (submucosal) ... uterine artery embolization (UAE) but usually dont cause major complications, ... 49 patients with 140 fibroids who underwent an MRI examination ... these were submucosal. Of these, 33% migrated to the endometrial ...
... Kwon Presents Urban Health Institute with 10,000 Sensual O Condom ... Mansion Fundraiser, LOS ANGELES, May 16 On Saturday, ... known best for his hit song "Everybody in the Club,Gettin, ... Sensual O Vibrating Condom Packs worth over $50,000. The donation ...
... May 16 Huntsworth plc (LSE: HNT), "the Group",a leading international public relations and healthcare ... the first quarter 2008 (the period,ending March 31, 2008)., The statement follows below., ... ... Interim Management Statement, ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) announced ... Vice President and Senior Investment Officer. "Dave,has made ... several years as,evidenced by our strong investment growth ... over $1 billion in accretive,investments for NHP, leveraging ...
... for at least a year or two, , , FRIDAY, ... people with type 1 diabetes live insulin-free for at ... longer-term improved metabolic control even after people have to ... glucose monitoring systems, researchers from the University of Miami ...
Cached Medicine News:Health News:Everybody in the Club Scream O! 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:David M. Boitano Promoted to Senior Vice President 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 3
Scleral blades designed for trabeculectomy and groove type incisions, scleral standard USA size....
Fechtner Trabeculectomy Marker...
... for Nystagmus when rotated at 8-10 ... 8" diameter. Light weight drum of ... effortless spin mechanism. For use 24 ... both Adult and Pediatric Drums that ...
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Medicine Products: